Search

A simple, rapid, accurate and precise spectrophotometric method has been developed for simultaneous estimation of Montelukast Sodium and Fexofenadine HCl in Pure and tablet dosage form. Proposed method involves formation of 'simultaneous equations' at 259.60nm for Fexofenadine Hydrochloride and 283.00 nm for Montelukast Sodium using methanol as a solvent. The linearity was observed in the concentration range of 30-120 mg/ml for Fexofenadine HCl and 6-20 mg/ml for Montelukast Sodium. The correlation coefficient was found to be 0.9927 for fexofenadine HCl and 0.9985 for Montelukast Sodium. Thus the proposed method is reproducible which can be suitably applied for the estimation of FEXO &MONT in combined dosage forms. The results of analysis have been validated statistically and by recovery studies. [ABSTRACT FROM AUTHOR]

• Coixol-based derivatives were designed and synthesized. • Screened in-vitro for insulin secretagogue effect. • The compound 14a and 34 were identified as most potent in insulin secretory effect. • The in vivo antidiabetic effect was significant in reduction of plasma glucose and total cholesterol level. • Histopathological examination showed improvement in the pancreatic tissues. Natural products have great potential for structural modifications to achieve the desired biological effect. In addition, these are considered safer, less expensive, and easily accessible compared to synthetic drugs. The natural compound coixol is a potent insulin secretagogue, obtained from the Plant parts of Scoparia dulcis and Coix lacryma jobi. In the present research work, we synthesized coixol-based derivatives that could potentially emerge as successful antidiabetic agents. Our previous work explains exclusive molecular docking studies based on the natural product coixol, which led to the current selection of twelve molecules comprising 2-benzoxazolinones, 2-benzimidazolinone, and benzimidazole-2-thiones with a good binding affinity toward ATP-sensitive potassium channel. All the synthesized molecules were screened for in vitro studies using a rat insulin ELISA assay. Wherein, Compounds 14a and 34 were identified as the most potent molecules with percentage insulin secretory concentrations of 162.43 and 227.16 µU/mL respectively which was reportedly higher than the standard drug Glibenclamide. The in vivo antidiabetic effect was checked using the streptozotocin-induced Type-II diabetes rat model, which revealed that test compounds 14a and 34 significantly reduced plasma glucose and total cholesterol levels and a marked increase in plasma insulin response was observed in diabetic rats. The histopathological examination at the end of the protocol also showed an improvement in the pancreatic tissue of diseased animals treated with test compounds 14a and 34. Thus, this research work indicates that the synthesized derivatives of coixol, 14a and 34 have good potential to be used for treating and managing Type-II diabetes in the future. [Display omitted] [ABSTRACT FROM AUTHOR]

The aim of the study is to develop and validate a simple, precise and rapid high performance thin layer chromatographic (HPTLC) method for Cefpodoxime Proxetil and Ofloxacin in bulk and combined tablet dosage form. Chromatographic separation was accomplished by using precoated silica gel 60F TLC plate (20cm x10cm) with 250Ām thickness with mobile phase Chloroform in ratio methanol (9:1 v/v). Detection was performed at isobestic point 255 nm for both drugs. The retesion factor of Cefpodoxime Proxetil and Ofloxacin were found to be 0.63 and 0.25, respectively. The reliability of the method was assessed by evaluation of linearity range (500-3000 ng/spot for both Cefpodoxime proxetil and ofloxacin respectively. Accuracy (99.56 % for Cefpodoxime Proxetil and 99.33% for Ofloxacin), and specificity, in compliance with ICH guidelines. [ABSTRACT FROM AUTHOR]

Glaucoma is one of the most common ophthalmic conditions encountered in primary and secondary care. The glaucoma is a group of progressive optic neuropathies characterized by degeneration of retinal ganglion cells and resulting changes in the optic nerve head. It is usually associated with an increase in intraocular pressure (IOP) above the normal value--usually estimated at 21 mm Hg. Loss of ganglion cells is related to the level of intraocular pressure, but other factors may also play a role. Reduction of intraocular pressure is the only proven method to treat the disease. Although treatment is usually initiated with ocular hypotensive drops, laser trabeculoplasty and surgery may also be used to slow disease progression. [ABSTRACT FROM AUTHOR]